The Reformulation of OxyContin and Availability of Substance Use Treatment Facilities in the United States

DiNardi, Michael (2025): The Reformulation of OxyContin and Availability of Substance Use Treatment Facilities in the United States.

Abstract

I examine how the substance use treatment sector responded to the abuse-deterrent reformulation of OxyContin, which contributed to a shift from prescription opioid misuse to heroin and synthetic opioids. First, I document a national increase in substance use treatment facilities after the reformulation and a shift toward outpatient-only care. Medication-assisted treatment with buprenorphine and naltrexone grew strongly throughout the first and second waves of the opioid crisis, while opioid treatment programs providing methadone increased relatively modestly after the reformulation. To isolate the role of exposure to OxyContin’s reformulation, I use variation in states’ pre-reformulation OxyContin misuse rates in a continuous difference-in-differences design. I find that pre-reformulation misuse rates are associated with larger increases in substance use treatment facilities after the reformulation, particularly outpatient-only facilities, with limited evidence misuse rates the availability of medication-assisted treatment services or inpatient care across states. Medicaid expansion under the Affordable Care Act was associated with more substance use treatment facilities and this effect was stronger in states with higher misuse rates, while the expansion of substance use treatment facilities was lower in states with certificate-of-need laws, highlighting the importance of insurance and regulatory barriers in treatment access. Back-of-the envelope estimates suggest the additional SUT facilities averted 2,700-7,800 overdose deaths between 2011 and 2019, corresponding to a value of $36-102 billion.

• Item Type: MPRA Paper
• Language: English
• Keywords: OxyContin, opioids, substance use, substance use treatment
• Subjects: I - Health, Education, and Welfare > I1 - Health > I11 - Analysis of Health Care Markets; I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health

References

Alpert, A., Evans, W. N., Lieber, E. M. J., and Powell, D. 2022. Origins of the Opioid Crisis and its Enduring Impacts. The Quarterly Journal of Economics, 137(2): 1139-1179.

Alpert, A., Powell, D., and Pacula, R. L. 2018. Supply-side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-deterrent Opioids. American Economic Journal: Economic Policy, 10(4): 1-35.

Bailey, J., Lu, T., and Vogt, P. 2022. Certificate-of-need Laws and Substance Use Treatment. Substance Abuse Treatment, Prevention, and Policy, 17: 38.

Beheshti, D. 2019. Adverse Health Effects of Abuse-deterrent Opioids: Evidence from the Reformulation of OxyContin. Health Economics, 28(12): 1449-1461.

Callaway, B., Goodman-Bacon, A., and Sant’Anna, P. H. 2024. Difference-in-differences with a Continuous Treatment. National Bureau of Economic Research, Working Paper No. 32117. http://www.nber.org/papers/w32117.

Cheetham, A., Picco, L., Barnett, A., Lubman, D. I., and Nielsen, S. 2022. The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy. Substance Abuse and Rehabilitation, 13: 1-12.

Cho, D., Garcia, D., Montes, J. and Weingarden, A. 2021. Labor Market Effects of the Oxycodone-Heroin Epidemic. Finance and Economics Discussion Series 2021-025. Washington: Board of Governors of the Federal Reserve System, https://doi.org/10.17016/FEDS.2021.025.

Cicero, T. J., Ellis, M. S., and Harvey, J. 2015. Shifting Patterns of Prescription Opioid and Heroin Abuse in the United States. New England Journal of Medicine, 373: 1789-1790.

Cicero, T. J., Ellis, and Surratt. H. L. 2012. Effect of Abuse-deterrent formulation of OxyContin. New England Journal of Medicine, 367: 187-189.

Connery, H. S. 2015. Medicaid-assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions. Harvard Review of Psychiatry, 23(2): 63-75.

Coplan, P. M., Kale, H., Sandstrom, L., Landau, C., and Chilcoat, H. D. 2013. Changes in Oxycodone and Heroin Exposures in the National Poison Data System after Introduction of Extended-release Oxycodone with Abuse-deterrent Characteristics. Pharmacoepidemiology and Drug Safey, 22: 1274-1282.

Corredor-Waldron, A. and Currie, J. 2022. Tackling the Substance Use Disorder Crisis: The Role of Access to Treatment Facilities. Journal of Health Economics, 81: 102579.

DiNardi, M. 2021. The Release of Abuse-deterrent OxyContin and Adolescent Heroin Use. 2021. Drug and Alcohol Dependence, 229(Part B): 109114.

DiNardi, M., Swann, W. L., and Kim, S. Y. 2022. Racial/ethnic Residential Segregation and the Availability of Opioid and Substance Use Treatment Facilities in US Counties, 2009-2019. SSM – Population Health, 20: 101289.

Evans, M. F., Harris, M. C., & Kessler, L. M. (2022). The Hazards of Unwinding the Prescription Opioid Epidemic: Implications for Child Maltreatment. American Economic Journal: Economic Policy, 14(4), 192–231.

Evans, W. N., Lieber, E. M. J., and Power, P. 2019. How the Reformulation of OxyContin Ignited the Heroin Epidemic. Review of Economics and Statistics, 101(1): 1-15.

Fardone, E., Montoya, I. D., Schackman, B. R., and McCollister, K. E. 2023. Economic Benefits of Substance Use Disorder Treatment: A Systematic Literature Review of Economic Evaluation Studies from 2003 to 2021. Journal of Substance Use & Addiction Treatment, 152: 209084.

Goedel, W. C., Shapiro, A., Cerda, M., Tsai, J. W., Hadland, S. E., and Marshall, B. D. 2020. Association of Racial/Ethnic Segregation with Treatment Capacity for Opioid Use Disorder in Counties in the United States. JAMA Network Open, 3(4): e203711.

Goodman-Bacon. 2021. Difference-in-differences with Variation in Treatment Timing. Journal of Econometrics, 225(2): 254-277.

Grooms, J. and Ortega, A. 2019. Examining Medicaid Expansion and the Treatment of Substance Use Disorders. American Economic Association Papers and Proceedings, 109: 187-191.

Heflin, C. and Sun, X. 2023. Food Insecurity and the Opioid Crisis. The ANNALS of the American Academy of Political and Social Science, 703(1): 262-284.

Horn, B. P., Joshi, A., and Maclean, J. C. 2021. Substance Use Disorder Treatment Centers and Residential Property Values. American Journal of Health Economics, 7(2): 185-221.

Jackson, J. R., Harle, C. A., Silverman, R. D., Simon, K., and Menachemi, N. 2020. Characterizing Variability in State-level Regulations Governing Opioid Treatment Programs. Journal of Substance Abuse Treatment, 115: 108008.

Jehan, S., Zahnd, W. E., Wooten, N. R., and Seay, K. D. 2024. Geographic Variation in Availability of Opioid Treatment Programs across U.S. Communities. Journal of Addictive Diseases, 42(2): 136-146.

Krawczyk, N., Rivera, B. D., Jent, V., Keyes, K.M, Jones, C. M., and Cerda, M. 2022. Has the Treatment Gap for Opioid Use Disorder Narrowed in the U.S.?: A Yearly Assessment from 2010 to 2019. International Journal of Drug Policy, 110: 103786.

Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L. Clark, T. W., and Alexander, G. C. 2015. The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction. Annual Review of Public Health, 36: 559-574.

Mackenzie-Liu, M. 2021. From Fostering Hope to Lingering Harm: The Unintended Impact of OxyContin Reformulation on Child Welfare Utilization. Social Service Review, 95: 35-65.

Maclean, J. C., Mallat, J., Ruhm, C. J., and Simon, K. 2021. Economic Studies on the Opioid Crisis: A Review. National Bureau of Economic Research, Working Paper No. 28067. http://www.nber.org/papers/w28067.

Mallat, J. 2022. Policy-induced Substitution to Illicit Drugs and Implications for Law Enforcement Activity. American Journal of Health Economics, 8: 30-64.

Noh, S. and Brown, C. H. 2018. Factors Associated with the Number of Substance Abuse Nonprofits in the U.S. States: Focusing on Medicaid Expansion, Certificate of Need, and Ownership. Nonprofit Policy Forum, 9(2): 20170010.

Park, S. and Powell, D. 2021. Is the Rise in Illicit Opioids Affecting Labor Supply and Disability Claiming Rates?. Journal of Health Economics, 76: 102430.

Powell, D. 2023. Growth in Suicide Rates Among Children During the Illicit Opioid Crisis. Demography, 60(6): 1843-1875.

Powell, D. and Pacula, R. L. 2021. The Evolving Consequences of OxyContin Reformulation on Drug Overdoses. American Journal of Health Economics, 7(1): 41-67.

Reuter, P., Caulkins, J. P., and Midgette, G. 2021. Heroin Use Cannot be Measured Adequately with a General Population Survey. Addiction, 116(10): 2600-2609.

Ryan, O., D. Murphy, and L. Krom. “Vital Signs: Taking the Pulse of the Addiction Treatment Workforce, A National Report.” Version 1. Kansas City, MO: Addiction Technology Transfer Center, National Office in residence at the University of Missouri-Kansas City, 2012

Takahashi, L. M. and Dear, M. J. 1997. The Changing Dynamics of Community Opposition to Human Service Facilities. Journal of the American Planning Association, 63(1): 79-93.

Saloner, B. and Maclean, J. M. 2020. Specialty Substance Use Disorder Treatment Admissions Steadily Increased in the Four Years After Medicaid Expansion. Health Affairs, 39(3): 453-461.

Substance Abuse and Mental Health Services Administration. 2020a. Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health. HHS Publication No. PEP20-07-01-001, NSDUH Series H-55. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/.

Substance Abuse and Mental Health Services Administration. 2020b. National Survey of Substance AbuseTreatment Services (N-SSATS): 2019. Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration.

Swann, W., DiNardi, M., and Schreiber, T. 2022. Association Between Inter-organizational Collaboration and Treatment Capacity for Opioid Use Disorder in Counties of Five States. Substance Abuse: Research and Treatment, 16: 1-13.

Swensen, I. 2015. Substance-abuse Treatment and Mortality. Journal of Public Economics, 122: 13-30.

U.S. Congress, Joint Economic Committee. 2017. The Cost of the Opioid Crisis: The Impact on the Labor Market and the Economy. Washington, DC: U.S. Joint Economic Committee. https://www.jec.senate.gov/public/_cache/files/67bced7f-4232-40ea-9263-f033d280c567/jec-cost-of-opioids-issue-brief.pdf.

U.S. Department of Health and Human Services. 2015. Examining Substance Use Disorder Treatment Demand and Provider Capacity in a Changing Health Care System: Initial Findings Report. Available at https://aspe.hhs.gov/sites/default/files/migrated_legacy_files//146281/ExamSUD.pdf. Accessed April 14, 2025.

U.S. General Accounting Office. 2003. Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem. GAO-04-110. Washington, DC: U.S. General Accounting Office, 2003. https://www.gao.gov/assets/gao-04-110.pdf.

Van Zee, A. 2009. The Promotion and Marking of OxyContin: Commercial Triumph, Public Health Tragedy. American Journal of Public Health, 99(2): 221-277.

Wakeman S.E., Larochelle M.R., Ameli O., Chaisson, C. E., McPheeters, J. T., Crown, Wi. H., Azocar, F., and Sanghavi, D. M. 2020. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Network Open, 3(2): e1920622. doi:10.1001/jamanetworkopen.2019.20622